Gilead and Kite Oncology Present Important New Data Across M

– Real-World Evidence and New Clinical Analysis Support the Role of Trodelvy® in Metastatic Breast Cancers –


– New Data Demonstrate Potential of Trodelvy in Small Cell Lung Cancer,...

Related Keywords

Foster City , California , United States , Barcelona , Comunidad Autonoma De Cataluna , Spain , Salamanca , Castillay Leóp , Frank Neumann , Santa Monica , Enfortumab Vedotin , Axicabtagene Ciloleucel , Gilead Sciences Inc , European Union , Nasdaq , Exchange Commission , European Society For Medical Oncology , Gilead Sciences , Gilead Company , Global Head Of Clinical Development , Gilead Public Affairs , Dana Farber Cancer Institute , European Society , Medical Oncology , Bill Grossman , Senior Vice President , Therapeutic Area Head , Matching Adjusted Indirect Comparison , Global Head , Clinical Development , Accepted Abstracts , World Treatment , Survival Outcomes , Previously Untreated Patients , Metastatic Triple Negative Breast Cancer , Safety Analyses , Prior Lines , Sacituzumab Govitecan , Breast Cancer , Use Patterns , Later Treatment , Adjusted Indirect Comparison , Largeb Cell Lymphoma , Least Two Prior Systemic Therapies , Double Antibody Drug Conjugate , Phasei Trial , Plus Enfortumab Vedotin , Second Line Therapy , Metastatic Urothelial Carcinoma , Advanced Head , Neck Squamous Cell Carcinoma , Results From , Extensive Stage Small Cell Lung Cancer , Preliminary Results From , Safety Information , Withhold Trodelvy , Infusion Related Reactions , Adverse Reactions , Fetal Toxicity , Prescribing Information , Release Syndrome , Risk Evaluation , Mitigation Strategy , Private Securities Litigation Reform Act , Quarterly Report , Markets ,